Anhui Province officially announced volume purchases!

On December 24, 2019, Anhui Provincial Medical centralized purchase service center issued the implementation plan of negotiation and negotiation (pilot) for centralized purchase of some commonly used drugs and the second batch of anticancer drugs in public medical institutions affiliated to Anhui Province in 2019, which was jointly initiated by Anhui Provincial Medical Insurance Bureau, provincial health and Health Commission, Provincial Department of Finance and provincial drug administration In addition, according to the official website of Anhui Medical Security Bureau, the policy interpretation meeting organized by Anhui Medical Security Bureau has been held in Hefei today, attended by medical security bureaus of all provinces and cities, heads of provincial public medical institutions, and representatives of relevant enterprises According to the announcement issued by Anhui Provincial Pharmaceutical centralized procurement service center, the implementation scope of this volume procurement is gradually extended to non-profit medical institutions (hereinafter referred to as public medical institutions) held by the people's government at or above the county level, state-owned enterprises (including state-owned holding enterprises) and other state-owned medical institutions In principle, the procurement cycle is two years From the perspective of procurement scope, there are two types of drugs participating in this volume procurement, namely, 90% of the total procurement of antibiotics (cephalosporins and related drugs) chemicals in provincial public medical institutions in 2018 and 80% of the second batch of anti-tumor chemicals On this basis, combined with the procurement situation in the first half of 2019 and the opinions of clinical experts, select the volume procurement catalogue According to the minutes of a meeting circulated today by "Anhui pharmaceutical junta", the former involves 66 drugs, while the latter involves 47 drugs, with a total of 113 varieties From the perspective of procurement method, the negotiation entry price will be set for this volume procurement Specifically, the experts will demonstrate and negotiate the entry price of negotiated drugs for volume procurement by referring to the lowest price of provincial bidding since 2016, the median price, average price, lowest price of the actual purchase price of provincial public medical institutions in 2018 and the first price of "two vote system" The enterprises that confirm to accept the negotiated drug price shall be regarded as shortlisted enterprises According to the official website of Anhui Medical Security Bureau, after the policy interpretation meeting, the drug companies involved in the negotiation have received the shortlisted price, and many enterprise representatives expressed their wishes to join the subsequent negotiation and negotiation in Anhui Province From the perspective of purchase quantity, this volume purchase will be based on the purchase quantity submitted by the provincial public medical institutions, and estimate the total purchase quantity according to 60% - 70% of the total annual consumption of drugs successfully negotiated by the provincial public medical institutions, and carry out volume purchase Provincial public medical institutions sign volume purchase and sale contracts with production enterprises according to the volume purchase negotiation price For the remaining dosage, provincial public medical institutions can still purchase other online drugs with appropriate price on the provincial drug purchase platform It is worth noting that in order to promote the smooth implementation of this policy, Anhui Medical Insurance Bureau and so on have issued a series of safeguard measures, including focusing on monitoring and early warning, prohibiting secondary bargaining, and formulating medical insurance payment standards First of all, for drugs that have been included in the negotiation and price negotiation, if the enterprise does not participate in the negotiation or the negotiation is unsuccessful, all specifications and packaged drugs of the same generic name and dosage form of the drug manufacturer are listed in the monitoring and early warning catalogue, and the purchase and use of drugs are monitored with emphasis, and the key monitoring drug management measures will be formulated separately.